


Catalog # 10-3306

Mocetinostat

CAS# 726169-73-9 N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide MGCD0103 Lot # X107856



Class I, isoform-selective HDAC inhibitor, $IC_{50}s=0.15$, 0.29, 1.66 and 0.59 μ M for HDAC1, 2, 3 and 11 respectively.¹ Induces hyperacetylation of histones, induces expression of the tumor suppressor p21WAF1 and inhibits proliferation of human cancer cells.² Displays antifibrotic effects in ischemic heart failure.³ Attenuates the development of hypersensitivity in models of neuropathic pain.⁴ Active *in vivo.*⁵

- 1) Zhou et al. (2008), Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ulpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor, J. Med. Chem., **51** 4072
- Raeppel et al. (2009), SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2aminophenyl)-4((4-(pyridine-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103); Bioorg. Med. Chem. Lett., 19 644
- Nural-Guvener et al. (2015), Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure; Int. J. Mol. Sci., 16 11482
- 4) Denk et al. (2013), HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain; Pain, **154** 1668
- 5) Bonfils *et al.* (2008), *Evaluation of the pharmacodynamics effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay;* Clin. Cancer Res., **14** 3441

PHYSICAL DATA

Molecular Weight:	396.44
Molecular Formula:	C ₂₃ H ₂₀ N ₆ O
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 25 mg/ml)
Physical Description:	Off-white solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in
	DMSO may be stored at -20°C for up to 2 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.